PLx Pharma - PLXP Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PLXP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PLXP, but not buy additional shares or sell existing shares.
View PLXP analyst ratings or view top-rated stocks.

3 analysts have issued 1-year target prices for PLx Pharma's stock. Their PLXP share price forecasts range from $12.00 to $12.00. On average, they predict the company's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 3,328.6% from the stock's current price.
View analysts price targets for PLXP or view top-rated stocks among Wall Street analysts.

PLx Pharma's stock was trading at $8.01 on January 1st, 2022. Since then, PLXP stock has decreased by 95.6% and is now trading at $0.35.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, March 10th 2023.
View our PLXP earnings forecast.

PLx Pharma Inc. (NASDAQ:PLXP) posted its earnings results on Friday, November, 12th. The biotechnology company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.09. The biotechnology company had revenue of $6.60 million for the quarter, compared to analysts' expectations of $4.10 million. PLx Pharma had a negative trailing twelve-month return on equity of 291.11% and a negative net margin of 606.91%. PLx Pharma's revenue for the quarter was up 560.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.40) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other PLx Pharma investors own include Energy Transfer (ET), Fulcrum Therapeutics (FULC), CymaBay Therapeutics (CBAY), VIVUS (VVUS), Paratek Pharmaceuticals (PRTK), Sorrento Therapeutics (SRNE), Cornerstone Strategic Value Fund (CLM), NewLink Genetics (NLNK), SCYNEXIS (SCYX) and Viking Therapeutics (VKTX).

(PLXP) raised $68 million in an IPO on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James acted as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."

PLx Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Two Sigma Advisers LP (0.70%), Green Square Capital Advisors LLC (0.66%), University of Texas Texas AM Investment Managment Co. (0.43%), Shufro Rose & Co. LLC (0.28%), O Brien Greene & Co. Inc (0.23%) and Two Sigma Investments LP (0.20%). Insiders that own company stock include John Hadden, Michael J Valentino, Natasha Giordano and Rita M O'connor.
View institutional ownership trends.

Shares of PLXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PLXP stock can currently be purchased for approximately $0.35.

PLx Pharma (NASDAQ:PLXP) has a market capitalization of $10.20 million and generates $8.21 million in revenue each year. The biotechnology company earns $-46,130,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis.

PLx Pharma's mailing address is 9 Fishers Lane Suite E, Sparta NJ, 07871. The official website for the company is www.plxpharma.com. The biotechnology company can be reached via phone at (973) 409-6541, via email at lwilson@insitecony.com, or via fax at 713-842-3052.